Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.56 |
| ▸ | TIPARP | Q7Z3E1 | 4/20 | 0.41 |
| ▸ | COMT | P21964 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30107626 | 1.00 | DAO (0.56) | DAOTIPARPCOMTKMT2AMCHR1 | |
| Luvadaxistat SCHEMBL14719667 | 0.84 | DAO (0.48) | DAOCOMTGPR84 | |
| SCHEMBL20314063 | 0.82 | DAO (0.53) | DAOCCNE1CDK2 | |
| SCHEMBL14718548 | 0.80 | DAO (0.47) | DAOTIPARPGPR84 | |
| SCHEMBL16234186 | 0.80 | DAO (0.41) | DAOTIPARPCOMTGPR84 | |
| SCHEMBL30159558 | 0.80 | DAO (0.52) | DAOTIPARP | |
| SCHEMBL14718319 | 0.80 | DAO (0.52) | DAOTIPARPGPR84 | |
| SCHEMBL30107664 | 0.80 | DAO (0.52) | DAOTIPARPGPR84 | |
| SCHEMBL14719057 | 0.80 | DAO (0.52) | DAOTIPARPCOMTGPR84KDM4E | |
| SCHEMBL30159621 | 0.80 | DAO (0.52) | DAOTIPARPCOMTGPR84KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-05 | — | — | US | claimed |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-28 | — | — | US | claimed |
| EP-3113778-B1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-06 | — | — | EP | claimed |
| US-9931340-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-03 | — | — | US | claimed |
| EP-2748149-B9 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-11-15 | — | — | EP | claimed |
| US-20170173007-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | claimed |
| US-20170014407-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTON OR TREATMENT OF AN ATAXIC DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-19 | — | — | US | claimed |
| EP-3113778-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER | Takeda Pharmaceutical Company Limited (JP) | 2017-01-11 | — | — | EP | claimed |
| US-9290456-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-22 | — | — | US | claimed |
| EP-2748149-B1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-10-21 | — | — | EP | claimed |
| WO-2015132608-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-11 | — | — | WO | claimed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | claimed |
| EP-2748149-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2014-07-02 | — | — | EP | claimed |
| WO-2013027000-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | claimed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | claimed |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-07 | — | — | US | disclosed |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| WO-2013027000-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052281-A1 | NOVEL COMPOUNDS | ABCG2, F12, UGT1A1 | DAO 4565/4885TIPARP 4605/4885COMT 1279/4885 |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885TIPARP 2494/4885COMT 358/4885 |
| US-20170014407-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTON OR TREATMENT OF AN ATAXIC DISORDER | ATXN2, CLN6, ATXN10 | DAO 1144/4885TIPARP 2639/4885COMT 1270/4885 |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | DAO 2/4885TIPARP 2494/4885COMT 358/4885 |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885TIPARP 2494/4885COMT 358/4885 |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | DAO 2/4885TIPARP 2494/4885COMT 358/4885 |
| US-20170173007-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885TIPARP 2494/4885COMT 358/4885 |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885TIPARP 2494/4885COMT 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.